Gennova, which is developing a potential indigenous mRNA COVID-19 vaccine called HGCO19, has initiated the enrolment of volunteers for Phase I and II clinical trials for its mRNA vaccine candidate. The vaccine has successfully completed animal trials and the clinical trials are expected to be completed in the next two-three months.

Leave a Reply

Your email address will not be published. Required fields are marked *